Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.96 +0.26 (+0.77%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
White House Commits $3B To Boost COVID-19 Vaccine Supply Chain: Report
The U.S. will invest $3 billion in the COVID-19 vaccine supply chain within the coming weeks, White House coronavirus response coordinator Jeff Zients said Thursday.... 
Via Benzinga
Exposures COVID-19
Can Vaccine Help In Long Term COVID-19 Symptoms? UK Study Gives Encouraging Answer
According to findings from a new U.K. study, along with reducing the risk of severe disease and hospitalization, COVID-19 vaccines can also lower the odds of having long-term... 
Via Benzinga
Exposures COVID-19
The Rising Delta Variant
China is not only cracking down on kiddie playtime. It also is absorbing bankruptcy claims from real estate developer Evergrande. 
Via Talk Markets
Topics Bankruptcy
Exposures Financial Legal
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
Exposures COVID-19
Friday: Quick Update
Britain - which I actually will be escaping soon - had a better market day than many foreign markets. 
Via Talk Markets
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
3 Things About Pfizer That Smart Investors Know
They're all about the future. 
Via The Motley Fool
This Biotech Company Could Offer Nearly Unlimited Optionality
Backed by its growing genetic database, 23andMe could take its business in a number of lucrative directions. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
EU Says Without EMA Approval COVID-19 Boosters May Face Higher Legal Risks: Reuters
European Union countries that decide to use COVID-19 vaccine booster shots may face increased legal risks, the European Commission said. Related Content: Pfizer, BioNTech... 
Via Benzinga
Exposures COVID-19
5 Best Dividend Stocks To Buy Now
There's no better time than now to invest in dividend stocks. And some of the best dividend stocks that beat the S&P 500's average yield of 2% can be found in the healthcare sector. 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
The second-quarter earnings season was a strong one for the drug/biotech sector. 
Via Talk Markets
Theravance Stock Crashes; Can Longer Testing Salvage Its J&J-Partnered Drug?
Theravance said late Monday its ulcerative colitis treatment failed in midstage testing, and the biotech stock plummeted early Tuesday. 
Via Investor's Business Daily
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the... 
Via Benzinga
Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia
The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab,... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues,... 
Via Benzinga
Exposures Product Safety
2 SPACs That Look Like Bargains After Post-Earnings Drops
Many recent SPAC IPOs have been hammered, and these two could be worth a closer look. 
Via The Motley Fool
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by... 
Via Benzinga
Exposures Product Safety
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
Exposures COVID-19
GlaxoSmithKline PLC Looks To Continue To Trade Above Its Annual-High Share Price Today
GlaxoSmithKline PLC (NYSE: GSK) traded at a new 52-week high today of $42.68. This new high was reached on below-average trading volume as 1.4 million shares traded hands, while... 
Via Benzinga
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) was the largest company by market cap to set a new 52-week... 
Via Benzinga
4 High-Yield Dividend Stocks to Boost Your Dividend Income
Dividends paid by GlaxoSmithKline plc, Vector Group Ltd, Star Group, L.P., and Ennis, Inc translate to high yields at their current price levels. 
Via Talk Markets
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Sunday Update - UK Disarray, Brazilian Kisses
News from the UK, China and Brazil, with the latest from Cosan. 
Via Talk Markets
Friday the Thirteenth
The stock week in points eastward was mixed. The USA markets face a bear correction. 
Via Talk Markets
82 Firms Going Ex-Dividend Next Week, Including Target, Walgreens Boots Alliance and GlaxoSmithKline
There are several well-known large-cap stocks going ex-dividend next week. 
Via Talk Markets
Do mRNA COVID-19 Vaccines Cause Skin Or Kidney Disorders? EMA Investigates Possible Links
The European Medicines Agency is investing a possible link between mRNA vaccines and erythema multiforme or two kidney disorders by a few recipients of the shots.... 
Via Benzinga
Exposures COVID-19
The Real World
The rise of the delta has caused markets to drop back after the rises earlier although inflation still remains within a point or two of forecasts at 5.3-5.4% annualized. 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.